Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769920 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation TTHX1114 Ophthalmic Solution
A Phase 1 study of Corneal Epithelial Degeneration, sponsored by Trefoil Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05769920 is a Phase 1 study of Corneal Epithelial Degeneration that has completed, run by Trefoil Therapeutics. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05769920, a Phase 1 study of Corneal Epithelial Degeneration, has completed, sponsored by Trefoil Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Dose escalation 3+3 design with accelerated titration 4 dose levels
Conditions Studied
Interventions
- DRUG TTHX1114(NM141) Ophthalmic Solution
Study Locations (1)
California
- Trefoil Clinical Site #132 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769920
The ClinicalTrials.gov registry entry for NCT05769920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trefoil Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Corneal Epithelial Degeneration appearing as the primary indexed condition, and to 1 intervention - of which TTHX1114(NM141) Ophthalmic Solution is the first listed.
NCT05769920 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05769920 about?
NCT05769920 is a clinical study titled "Dose Escalation TTHX1114 Ophthalmic Solution". Dose escalation 3+3 design with accelerated titration 4 dose levels
What is the current status of trial NCT05769920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-12-06. Estimated completion is 2023-04-12.
What conditions does trial NCT05769920 study?
This clinical trial studies the following conditions: Corneal Epithelial Degeneration.
What interventions are being tested in trial NCT05769920?
The interventions under investigation include: TTHX1114(NM141) Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05769920?
This trial is sponsored by Trefoil Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.